Journal
DRUG DISCOVERY TODAY
Volume 19, Issue 12, Pages 1936-1944Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2014.08.012
Keywords
-
Categories
Ask authors/readers for more resources
Positron emission tomography (PET) is routinely used to support the development of drugs to treat neurological and psychiatric disorders. PET radioligands must not only be selective for the target of interest but must also possess a range of physicochemical and pharmacological characteristics that allow them to be radiolabelled with short-lived positron-emitting isotopes, safely administered to humans, and for the degree of target binding to be quantified in vivo. We review the ligand development process, including target selection, radioligand discovery (in vitro and preclinical evaluation), radiochemistry and evaluation in humans.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available